New Migraine Medication.

New Migraine Medication. Am J Nurs. 2020 Feb;120(2):20-21 Authors: Aschenbrenner DS PMID: 31977411 [PubMed - in process]
Source: The American Journal of Nursing - Category: Nursing Authors: Tags: Am J Nurs Source Type: research

Related Links:

In this study, we seek to characterize the complex interaction of intracranial compartments and contributors to intracranial hypertension.
Source: Journal of Vascular and Interventional Radiology : JVIR - Category: Radiology Authors: Tags: Scientific e-Poster Source Type: research
Objectives: To compare habituation in auditory middle latency response (AMLR) to repetitive stimuli of vestibular migraine (VM) patients with Meniere's disease (MD) patients and healthy controls (HC) and to assess usefulness of AMLR for diagnosis of VM.Subjects: Thirteen unilateral definite MD patients (2 men, 11 women, mean age 50.6), 13 definite VM patients (3 men, 10 women, mean age 45.5), and 8 HC subjects (2 men, 6 women, mean age 37.1) were enrolled.Methods: The electrodes were placed on the vertex and the spinal process of the fifth cervical vertebra. Binaural click stimulation (0.1 ms, 70 dBnHL) was presented. A to...
Source: Frontiers in Neurology - Category: Neurology Source Type: research
Authors: Lisicki M, Schoenen J Abstract Introduction: Most preventive migraine treatments modify the brain's excitation/inhibition balance and/or serotonin metabolism, which likely accounts for their unfavourable adverse effect profile. Novel biological therapies blocking CGRP transmission are effective and much better tolerated, but they are expensive and may not influence brain dysfunctions upstream in the pathophysiological cascade of migraine, including premonitory and aura symptoms. Biochemical and clinical studies suggest that there may be another complimentary treatment strategy, the one that targets the undere...
Source: Expert Review of Neurotherapeutics - Category: Neurology Tags: Expert Rev Neurother Source Type: research
The complex mechanisms underlying migraine are not entirely understood. It has been suggested that descending endogenous pain modulation is an important contributing factor, although research is controversial. A frequently used method to quantify the inhibitory pain modulation system is offset analgesia (OA), defined as a disproportionally large decrease in pain perception in response to a small decrease of painful stimulation. The aim of this study is to evaluate the OA response in patients with migraine and healthy controls, measured at the forehead (trigeminal, V1) and forearm (extratrigeminal). Patients with episodic m...
Source: Pain - Category: Anesthesiology Tags: Research Paper Source Type: research
We describe three cases of lymphoma in which lymphoma mimicked other diseases causing neurological dysfunction, specifically sarcoidosis, vasculitis and infection respectively. Case 1 was a 66-year-old man with subacute progressive diplopia and gait disturbance and investigations revealing a supratentorial para-falcine soft tissue lesion, mid-thoracic cord enhancement and right axillary mass and an elevated serum ACE. Right axillary mass core biopsy was diagnostic of Burkitt lymphoma. Case 2 was a 50-year-old man with several weeks of constitutional symptoms and development of lower limb weakness and numbness, urinary rete...
Source: Journal of Clinical Neuroscience - Category: Neuroscience Source Type: research
Conditions:   Tension-Type Headache;   Migraine Interventions:   Behavioral: ceprica;   Behavioral: ceprica control Sponsor:   Gaia AG Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
A 40-year-old male patient was admitted to the emergency department for persistent severe headache unrelieved by paracetamol. He had no medical history but reported asthenia and weight loss (2 kg) over the previous 3 weeks. At admission, blood pressure was 120/80 mm  Hg and physical examination was unremarkable. Laboratory blood tests showed: serum creatinine 1.7 mg/dl, sodium 141 mmol/l, calcium 9.2 mg/dl, C-reactive protein 6 mg/l, leucocytes 11520/mm3, neutrophils 9230/mm3, lymphocytes 1090/mm3, and hemoglobin 13.6 g/dl.
Source: Kidney International - Category: Urology & Nephrology Authors: Tags: Make Your Diagnosis Source Type: research
AbstractTo introduce a purely endoscopic endonasal trans-Meckel ’s cave approach or a transclival approach for trigeminal schwannomas (TSs) involving both the middle and posterior fossae. This retrospective study reviewed the medical records and intraoperative videos of 8 patients with TSs occupying both the middle and posterior fossae who underwent an endosco pic endonasal approach (EEA) between January 2017 and October 2019. All 8 patients received total resection under a single-stage EEA. Six patients underwent endoscopic endonasal resection via a purely trans-Meckel’s cave approach, and 2 patients underwent...
Source: Neurosurgical Review - Category: Neurosurgery Source Type: research
We report an increased burden of rare variants in one CpG island and three polycomb group response elements near four migraine risk loci. We found that the association is independent of the common risk variants in the loci. The regulatory regions are suggested to affect different genes than those originally tagged by the index SNPs of the migraine loci. Families with familial clustering of migraine have an increased burden of rare variants in regulatory regions near known migraine risk loci, with effects that are independent of the variants in the loci. The possible regulatory targets suggest different genes than those ori...
Source: Neurogenetics - Category: Genetics & Stem Cells Source Type: research
Abstract OBJECTIVE: To evaluate the efficacy of ubrogepant on patient-reported functional disability, satisfaction with study medication, and global impression of change. BACKGROUND: Ubrogepant is a small-molecule, oral calcitonin gene-related peptide receptor antagonist indicated for the acute treatment of migraine. In 2 phase 3 trials (ACHIEVE I and II), ubrogepant demonstrated efficacy vs placebo on the 2 co-primary endpoints of headache pain freedom and absence of the most bothersome migraine-associated symptom at 2 hours post dose for the 50 and 100 mg doses. Patient-reported outcomes, such as ...
Source: Headache - Category: Neurology Authors: Tags: Headache Source Type: research
More News: Headache | Migraine | Nurses | Nursing